Genenta Science S.p.A.
GNTA
Price:
$5.3
Market Cap:
$89.10M
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.[Read more]
Industry
Biotechnology
IPO Date
2021-12-15
Stock Exchange
NASDAQ
Ticker
GNTA
PE Ratio
[-10.00]
ROE
[-30.61%]
Current Ratio
[12.25]
Dividend Yield
[0%]
Enterprise Value
[85.40M]
Dividend History
The ROE as of November 2024 (TTM) for Genenta Science S.p.A. (GNTA) is -30.61%
According to Genenta Science S.p.A.’s latest financial reports and current stock price. The company's current ROE is -30.61%. This represents a change of 352.84% compared to the average of -6.76% of the last 4 quarters.
Genenta Science S.p.A. (GNTA) Historical ROE (quarterly & annually)
How has GNTA ROE performed in the past?
The mean historical ROE of Genenta Science S.p.A. over the last ten years is -28.87%. The current -30.61% ROE has changed 6.02% with respect to the historical average. Over the past ten years (40 quarters), GNTA's ROE was at its highest in in the June 2020 quarter at 0%. The ROE was at its lowest in in the June 2023 quarter at -27.00%.
Average
-28.87%
Median
-24.44%
Minimum
-56.95%
Maximum
-11.64%
Genenta Science S.p.A. (GNTA) ROE by Quarter and Year
Discovering the peaks and valleys of Genenta Science S.p.A. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 389.20%
Maximum Annual ROE = -11.64%
Minimum Annual Increase = -61.32%
Minimum Annual ROE = -56.95%
| Year | ROE | Change |
|---|---|---|
| 2023 | -56.95% | 389.20% |
| 2022 | -11.64% | -18.65% |
| 2021 | -14.31% | -61.32% |
| 2020 | -37.00% | 51.38% |
Genenta Science S.p.A. (GNTA) Average ROE
How has GNTA ROE performed in the past?
The current ROE of Genenta Science S.p.A. (GNTA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-27.63%
5-year avg
-28.87%
10-year avg
-28.87%
Genenta Science S.p.A. (GNTA) ROE vs. Peers
How is GNTA’s ROE compared to its peers?
Genenta Science S.p.A.’s ROE is greater than Molecular Partners AG (-33.08%), greater than MediciNova, Inc. (-13.37%), greater than Anebulo Pharmaceuticals, Inc. (-138.92%), less than Champions Oncology, Inc. (323.52%), greater than Cyteir Therapeutics, Inc. (-23.13%), greater than PMV Pharmaceuticals, Inc. (-21.96%), greater than Eliem Therapeutics, Inc. (-47.03%), greater than Pharvaris N.V. (-36.89%), greater than PepGen Inc. (-62.74%), greater than Mineralys Therapeutics, Inc. (-42.61%), greater than Janux Therapeutics, Inc. (-8.78%), greater than Rezolute, Inc. (-70.73%), less than Opthea Limited (0%), less than Pardes Biosciences, Inc. (360.15%), greater than AN2 Therapeutics, Inc. (-54.84%), greater than Aerovate Therapeutics, Inc. (-54.72%), greater than Adagene Inc. (-83.65%), greater than null (-50.10%),
| Company | ROE | Market cap |
|---|---|---|
| -33.08% | $247.30M | |
| -13.37% | $82.40M | |
| -138.92% | $49.01M | |
| 323.52% | $57.64M | |
| -23.13% | $108.71M | |
| -21.96% | $84.49M | |
| -47.03% | $342.68M | |
| -36.89% | $1.29B | |
| -62.74% | $221.28M | |
| -42.61% | $671.31M | |
| -8.78% | $2.91B | |
| -70.73% | $304.25M | |
| 0% | $628.43M | |
| 360.15% | $135.19M | |
| -54.84% | $32.23M | |
| -54.72% | $78.52M | |
| -83.65% | $135.03M | |
| -50.10% | $0 |
Build a custom stock screener for Genenta Science S.p.A. (GNTA) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Genenta Science S.p.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Genenta Science S.p.A. (GNTA) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Genenta Science S.p.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Genenta Science S.p.A.'s ROE?
How is the ROE calculated for Genenta Science S.p.A. (GNTA)?
What is the highest ROE for Genenta Science S.p.A. (GNTA)?
What is the 3-year average ROE for Genenta Science S.p.A. (GNTA)?
What is the 5-year average ROE for Genenta Science S.p.A. (GNTA)?
How does the current ROE for Genenta Science S.p.A. (GNTA) compare to its historical average?